Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$26.59 USD

26.59
1,844,197

-0.52 (-1.92%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Biogen (BIIB) Beat Estimates This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

Alkermes (ALKS) Q3 Earnings Match Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Alkermes (ALKS) closed the most recent trading day at $24.51, moving +0.62% from the previous trading session.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

by Zacks Equity Research

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

by Zacks Equity Research

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

LHC Group (LHCG) to Expand Access in Georgia With New Buyout

by Zacks Equity Research

LHC Group (LHCG) is set to acquire Georgia-based Three Rivers Home Health that will expand its service footprint in 36 counties in the state of Georgia.

Merck (MRK) Enters Into Circular RNA Collaboration With Orna

by Zacks Equity Research

Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.

DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice

by Zacks Equity Research

The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

Are Medical Stocks Lagging Alkermes (ALKS) This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Here's Why You Should Buy Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez

by Zacks Equity Research

CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.